
|Articles|August 1, 2003
Radiotherapy for subfoveal CNV has early, but not durable benefits
Author(s)Cheryl Guttman
Fort Lauderdale, FL-High-dose (5 3 4-Gy fractions; 6 MeV) external-beam radiation therapy has only a modest and very short-lived benefit in the treatment of subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), according to an interim analysis of data from the Age-Related Macular Degeneration Radiotherapy Trial (AMDRT).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
EURETINA 2026: Uveitis or retinitis pigmentosa? Ester Carreño, MD, PhD, on mimics
2
EURETINA 2026: Retinal signs as diagnostic clues to systemic metabolic disease
3
MOGENRY earns Japan priority review for inherited retinal dystrophies
4
What retinal imaging reveals about the brain-eye connection with Sharon Fekrat, MD, FACS, FASRS
5















